Overview

A Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis

Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
The study is comprised of two parts. The first portion of this study will be a double-blind, Sponsor-unblinded, vehicle-controlled study with application of ruxolitinib or vehicle to paired lesions at least 15 cm apart in patients with active but stable plaque psoriasis. Part 2 of the study is a double-blind, sponsor unblinded, comparison of ruxolitinib with two FDA approved products in patients with active but stable plaque psoriasis.
Phase:
Phase 2
Details
Lead Sponsor:
Incyte Corporation
Treatments:
Betamethasone
Betamethasone benzoate
Betamethasone sodium phosphate
Betamethasone Valerate
Betamethasone-17,21-dipropionate
Calcipotriene
Calcitriol